Meissa Vaccines develops live attenuated vaccine candidates against respiratory viruses, including respiratory syncytial virus (RSV) and COVID-19, using its proprietary AttenuBlock platform.

Meissa Vaccines

Meissa Vaccines | 1,309 followers on LinkedIn. Taming Viruses with ​Synthetic Biology | Meissa is a private biotech company focused on the advancement of vaccines for respiratory viruses. Meissa was founded on proprietary technologies employing reverse genetics for rational design of more effective live attenuated vaccines. The technology is exclusively licensed from Emory University and Children’s Healthcare of Atlanta.

Retired

Fiona Cameron

Viewport Meta

IPhone / Mobile Compatible

SSL by Default

Apple Mobile Web Clips Icon

HSTS

Content Delivery Network

LetsEncrypt

Organization Schema

Microsoft Exchange Online

Chief Scientific Officer

Martin Moore

Vice President Regulatory Affairs

Vice President of Operations

Janelle Muranaka

Vice President of Clinical Development

Jay Lieberman

Associate Director of Vaccine Discovery

Jia Meng

Sr. Director of Clinical Operations

Joseph Sulovski

Director, Quality

Phillip (PJ) Azcuna

Associate Director of Virology

Xing Cheng

Healthcare

Susan Farkas

Operations

Jacqueline Earabino, RN BSN

William Daly

Founder & CEO

Roderick Tang

Founder & Chief Scientific Officer

Marty Moore

Frank Glavin

Chief Executive Officer

West Coast Early Stage Companies With Fewer Than 100 Employees

Private West Coast Companies (Top 10K)

San Francisco Biotechnology Companies

Western US Companies With Less Than $50M in Revenue (Top 10K)

Meissa Vaccines is a start-up pharmaceutical development company focused on the in-licensing and advancement of vaccines for respiratory syncytial virus (RSV, the largest unmet respiratory medical need in pediatrics) and rhinovirus (leading cause of infectious disease worldwide). 
Their passion is child health, but our vaccine programs have the potential to benefit multiple age groups directly and indirectly. Successful vaccines for respiratory syncytial virus and rhinovirus would have widespread benefits for society and families. These include reducing the burden of acute lower respiratory tract disease, reducing colds, reducing acute asthma exacerbations caused by these viruses, and alleviating missed school and work.

Morningside Venture Investments

Series A - Meissa Vaccines

Seed Round - Meissa Vaccines

San Francisco

California

United States

North America

Layoffs at Meissa Vaccines as biotech's future lies in limbo

Growing RSV Vaccine Market: Rapid Urbanization and ...

Top 10 Contract Development and Manufacturing Organizations

Meissa Vaccines Announces Positive Interim Clinical Data...

Meissa Vaccines Appoints Frank Glavin Chief Executive Officer

Chimeric rsv and coronavirus proteins, immunogenic compositions, and methods of …

RSV AND CORONAVIRUS CHIMERIC PROTEINS, IMMUNOGENIC COMPOSITIONS, AND METHODS OF …

Meissa Vaccines Receives U.S. FDA Fast Track Designation for Respiratory Syncytial Virus Vaccine, MV-012-968

Meissa Vaccines gathers $30 mln Series A

An intranasal, live attenuated vaccine candidate designed to protect against RSV, showing immune response induction in clinical trials.

A live viral intranasal COVID-19 vaccine candidate aimed at inducing mucosal and systemic immunity against SARS-CoV-2.

A synthetic biology platform used for generating live attenuated vaccine candidates with enhanced immune response.

India

Asia

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 16, 2024 10:04 AM	63c35f8d
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 16, 2024 10:04 AM	cc69697a
crunchbase trigger	general	Nov 16, 2024 10:04 AM	5de98793
crunchbase profile	general	Nov 16, 2024 10:12 AM	e4be2b69
li profile	general	Nov 16, 2024 10:04 AM	4d49e96d
translate crunchbase fundingrounds	general	Nov 16, 2024 10:28 AM	30d88f99
peers	general	Nov 16, 2024 10:04 AM	f3f33697
news basic	general	Nov 16, 2024 10:04 AM	91310b69
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

MEIS

COM:MEISSAVACCINES

Meissa Vaccines